Through an Israeli innovation lab, four big pharma companies are fostering AI-driven start-ups to help solve industry problems.

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.